CareDx presented validation data from the observational ACROBAT study showing its AlloHeme cell‑free DNA assay for allogeneic hematopoietic cell transplant (HCT) surveillance achieved 85% sensitivity and 92% specificity versus clinical relapse, with a median 41‑day lead time to detect relapse. The study enrolled 285 transplant recipients across 11 U.S. sites; 198 were analyzable and 118 completed two‑year follow‑up. Investigators reported a 95% negative predictive value and 79% positive predictive value, outperforming traditional bone marrow biopsy sensitivity estimates cited by experts. CareDx plans commercial groundwork for AlloHeme ahead of a planned launch next year, contingent on publication of ACROBAT results. Company executives and academic co‑investigators highlighted the assay’s potential to shift monitoring paradigms in post‑HCT care by enabling earlier therapeutic intervention and reducing invasive testing.